AIM ImmunoTech Builds Positive Momentum and Reiterates Focus on Driving Ampligen® Clinical Development Toward Pancreatic Cancer Approval

Primary focus on pancreatic cancer Mid-year report of Ampligen® (rintatolimod) in combination with AstraZeneca's Imfinzi® (durvalumab) for the treatment of pancreatic cancer demonstrates positive signs of both no significant toxicity and superior PFS and OS Bolstered cash position provides runway to fund operations for approximately 12 months OCALA, Fla., Aug. 04, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) ("AIM" or the "Company") today highlighted recent key financial milestones and ...